In Systemic Sclerosis Patients, Peripheral Blood CD21(low) B Cells and Serum IL-4 and IL-21 Influence Joint Involvement

Systemic sclerosis (SSc) patients have an increased frequency of CD21(low) B cells and of serum interleukin-4 (IL-4) and IL-21, each possible markers of joint involvement in inflammatory arthritis. The aim of this study was to investigate the possible influence of CD21(low) B cells, IL-4, and IL-21 on joint involvement in a cohort of 52 SSc patients. The DAS28-ESR was correlated with CD21(low) B cells (r = 0.452, p < 0.001), IL-4 (r = 0.478, p < 0.001), and IL-21 (r = 0.415, p < 0.001). SSc patients with a DAS28-ESR > 3.2 had more CD21(low) B cells (12.65% (IQR: 7.11–13.79) vs. 5.08% (IQR: 3.76–7.45), p < 0.01), higher IL-4 levels (132.98 pg/mL (IQR: 99.12–164.12) vs. 100.80 pg/mL (IQR: 62.78–121.13), p < 0.05), and higher IL-21 levels (200.77 pg/mL (IQR: 130.13–302.41) vs. 98.83 pg/mL (IQR: 35.70–231.55), p < 0.01) than patients with a DAS28-ESR ≤ 3.2. The logistic regression analysis models showed that the DAI (OR: 2.158 (95% CI: 1.120; 4.156), p < 0.05) and CD21(low) B cells (OR: 1.301 (95% CI: 1.099; 1.540), p < 0.01), the DAI (OR: 2.060 (95% CI: 1.082; 3.919), p < 0.05) and IL-4 level (OR: 1.026 (95% CI: 1.006; 1.045), p < 0.01), and the DAI (OR: 1.743 (95% CI: 1.022; 2.975), p < 0.05) and IL-21 level (OR: 1.006 (95% CI: 1.000; 1.011), p < 0.05) were independently associated with a DAS28-ESR > 3.2. An elevated CD21(low) B cell percentage, IL-4 level, and IL-21 level was associated with higher articular disease activity in patients, suggesting a possible role in the pathogenesis of SSc joint involvement.